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Background
Characterizing neutralizing antibody (Nab) responses in
non-B HIV-1 subtypes is essential, because the data may
illustrate key genetic and antibody properties that could
impact the design and testing of Nab vaccine candidates
in countries where these subtypes circulate. The principle
objective of this study is to document the magnitude,
breadth and prevalence of neutralizing antibodies in a
cohort of non-B HIV chronically infected individuals in
rural Uganda.
Methods
45 treatment naive patients were randomly selected from
the Rural Clinical Cohort (RCC), which recruits HIV
infected individuals with known date of sero-conversion.
The average time of infection was 5.45 yrs (range 1–16
yrs). Two sample points were selected for each patient;
T1(early) and T2(late), and tested against two tier-1
strains of HIV-1 (SF162.LS, MW965.26) and MLV nega-
tive control virus; in the standardized TZM-bl neutraliza-
tion assay. MLV positive samples were excluded from
analaysis.
Results
Magnitude of the NAb response against SF162.LS(subtype
B) and MW965.26(subtype C) varied but was relatively
potent in a most cases (ID50 titers >1,000, range 20–
87,480). 30% of samples showed activity against SF162 at
T1 and 40% against MW965.26. At T2, a significant
increase in titers against both viruses was observed; 50%
neutralized SF162 and 65% neutralized MW965.26 (p =
0.001 and p = 0.0006 respectively). NAb titers against
both viruses were closely associated and increased signifi-
cantly (p <0.0012) from the early to late time point. The
magnitude of this increase was substantial in some sub-
jects, whereas in a few the response decreased over time.
Conclusion
A high prevalence of Nabs was detected. The magnitude
and long-term kinetics varied between subjects. Further
analysis with tier 2 viruses (4 As, 4 Bs, 4 Cs and 4 Ds) and
association with viral load and CD4 counts will be per-
formed to document the prevalence and kinetics of cross-
reactive neutralizing antibody responses.
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